Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

What is the optimal therapy for patients with H5N1 influenza?

White NJ, Webster RG, Govorkova EA, Uyeki TM.

PLoS Med. 2009 Jun 23;6(6):e1000091. doi: 10.1371/journal.pmed.1000091. Epub 2009 Jun 23.

2.

Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.

Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, Dutkowski R.

Adv Ther. 2011 Nov;28(11):927-59. doi: 10.1007/s12325-011-0072-7. Epub 2011 Nov 1. Review.

PMID:
22057727
3.

[Threat from newly emerging influenza].

Kashiwagi S.

Nihon Naika Gakkai Zasshi. 2007 Apr 10;96(4):811-6. Review. Japanese. No abstract available.

PMID:
17506323
4.

The use of antiviral agents for the management of severe influenza.

Smith JR, Ariano RE, Toovey S.

Crit Care Med. 2010 Apr;38(4 Suppl):e43-51. doi: 10.1097/CCM.0b013e3181c85229. Review.

PMID:
19935416
5.

[Etiotropic therapy of influenza: lessons from the last pandemic].

Kolobukhina LV, Shchelkanov MIu, Merkulova LN, Bazarova MV, Burtseva EI, Samokhvalov EI, Al'khovskiĭ SV, Prilipov AG, Fediakina IT, Proshina ES, Aristova VA, Morozova TN, Sutochnikova OA, Ponomarenko RA, Malyshev NA, Maslov AM, Chuchalin AG.

Vestn Ross Akad Med Nauk. 2011;(5):35-40. Russian.

PMID:
21786595
6.

Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.

Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA.

Antivir Ther. 2007;12(3):363-70.

PMID:
17591026
7.

Using oseltamivir (Tamiflu) as a first line treatment for seasonal or pandemic flu.

Greener M.

Nurs Times. 2009 Sep 1-7;105(34):22. No abstract available.

PMID:
19788111
8.

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

Ikematsu H, Kawai N.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Review.

PMID:
21973296
9.

Oseltamivir in the management of influenza.

Oxford J.

Expert Opin Pharmacother. 2005 Nov;6(14):2493-500. Review.

PMID:
16259580
10.

[Oseltamivir resistant avian influenza unsettling. Private hoarding of influenza agents a potential threat against public health].

Uhnoo I, Linde A.

Lakartidningen. 2006 Feb 1-7;103(5):298-300. Swedish. No abstract available.

PMID:
16512569
11.

Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections.

Escuret V, Cornu C, Boutitie F, Enouf V, Mosnier A, Bouscambert-Duchamp M, Gaillard S, Duval X, Blanchon T, Leport C, Gueyffier F, Van Der Werf S, Lina B.

Antiviral Res. 2012 Nov;96(2):130-7. doi: 10.1016/j.antiviral.2012.08.002. Epub 2012 Aug 14.

PMID:
22909899
12.

[Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].

Fediakina IT, Shchelkanov MIu, Deriabin PG, Leneva IA, Gudova NV, Kondrat'eva TV, L'vov DK.

Antibiot Khimioter. 2011;56(3-4):3-9. Russian.

PMID:
21913403
13.

Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.

Belser JA, Szretter KJ, Katz JM, Tumpey TM.

Virology. 2013 Apr 25;439(1):42-6. doi: 10.1016/j.virol.2013.01.017. Epub 2013 Mar 1.

14.

Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection.

Nakamura K, Schwartz BS, Lindegårdh N, Keh C, Guglielmo BJ.

Clin Infect Dis. 2010 Apr 1;50(7):e47-9. doi: 10.1086/651166.

15.

Determinants of antiviral effectiveness in influenza virus A subtype H5N1.

Chan PK, Lee N, Zaman M, Adisasmito W, Coker R, Hanshaoworakul W, Gasimov V, Oner AF, Dogan N, Tsang O, Phommasack B, Touch S, Bamgboye E, Swenson A, Toovey S, Dreyer NA.

J Infect Dis. 2012 Nov;206(9):1359-66. doi: 10.1093/infdis/jis509. Epub 2012 Aug 20.

16.

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.

Sugaya N, Ohashi Y.

Antimicrob Agents Chemother. 2010 Jun;54(6):2575-82. doi: 10.1128/AAC.01755-09. Epub 2010 Apr 5.

17.

[The new pandemic influenza A/H1N1. Antiviral agents for the initial stage--vaccine reduces the effects in the long run].

Uhnoo I, Bergquist C.

Lakartidningen. 2009 Jul 8-21;106(28-29):1814-9. Review. Swedish. No abstract available.

PMID:
19685621
18.

Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.

Wang SQ, Du QS, Huang RB, Zhang DW, Chou KC.

Biochem Biophys Res Commun. 2009 Aug 28;386(3):432-6. doi: 10.1016/j.bbrc.2009.06.016. Epub 2009 Jun 10.

PMID:
19523442
19.

Foreword: Oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience.

Nguyen-Van-Tam JS.

J Antimicrob Chemother. 2010 Apr;65 Suppl 2:ii3-ii4. doi: 10.1093/jac/dkq033. No abstract available.

20.

Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses.

Dharan NJ, Beekmann SE, Fiore A, Finelli L, Uyeki TM, Polgreen PM, Fry AM.

Antiviral Res. 2010 Nov;88(2):182-6. doi: 10.1016/j.antiviral.2010.08.010. Epub 2010 Aug 23.

PMID:
20739002
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk